Physician profile
Mark M Wilson
NPI 1295728087
$2,899.94
in general payments reported to CMS, 2019-2025
20 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $215 · 2021: $120 · 2022: $639 · 2023: $588 · 2024: $580 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Education: $29.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.38 |
| Education | $29.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $702.45 | 2020-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $335.56 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $277.01 | 2022-2025 | |
| Akebia Therapeutics INC | $182.66 | 2019-2023 | Auryxia |
| Fresenius USA Marketing, INC. | $164.00 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Amgen INC. | $151.56 | 2019-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $149.42 | 2022-2025 | Tarpeyo |
| Abiomed | $145.11 | 2022 | |
| Baxter Healthcare | $144.31 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $113.71 | 2019-2024 | Jynarque |
| Medtronic, INC. | $99.87 | 2024-2025 | Mcgrath Mac, Nellcor, Retia Medical |
| Opko Pharmaceuticals, LLC | $86.71 | 2019-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $75.38 | 2020-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.18 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $56.68 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.87 | 2020-2024 | |
| Travere Therapeutics, INC. | $43.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $33.12 | 2020-2022 | |
| Kyowa Kirin, INC. | $14.13 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.